GLP-1 Drugs and High-Output Stoma: What a 2026 Scoping Review Found

For many people living with a stoma, high output is one of the most disruptive and medically serious complications they can face. When a stoma produces significantly more fluid than expected, the consequences can include dehydration, electrolyte imbalances, malnutrition, and in some cases dependence on intravenous nutrition. Managing it can be difficult, and the available treatments do not always work quickly or well enough.

A 2026 scoping review published in The Journal of Surgical Research has examined whether a class of drugs that has become widely known for weight management, GLP-1 receptor agonists, could play a role in this setting. The short answer from the review is: early evidence is promising, but it is not yet conclusive.

What Is a High-Output Stoma?

A high-output stoma is generally defined as a stoma that produces more than 1,500 ml of output per day, though some clinical definitions use thresholds of 1,000 to 2,000 ml depending on the clinical setting and stoma type.

The NHS notes that high-output stoma can develop after surgery and that it requires prompt contact with a stoma care nurse or specialist team because of the risk of dehydration and electrolyte disturbance (NHS, ileostomy living with). High-output stoma occurs most commonly with ileostomies, where the colon is no longer present to reabsorb water and electrolytes from the intestinal content before it exits the body.

The downstream consequences, if not managed, can be severe: kidney injury from dehydration, dangerously low sodium or potassium levels, weight loss, and in persistent cases, dependence on parenteral nutrition delivered intravenously. Hospital readmission rates for high-output stoma are high.

Current Treatments and Their Limitations

Standard management for high-output stoma currently involves a combination of dietary adjustment, fluid management, and medications. The medications used fall into two broad categories: antisecretory agents, which reduce the volume of fluid secreted into the gut, and antimotility agents, which slow the movement of intestinal contents and allow more time for fluid absorption.

Commonly used drugs include loperamide, codeine phosphate, omeprazole (or other proton pump inhibitors), and octreotide in more severe cases. Oral rehydration solutions with specific electrolyte compositions are also central to management.

The 2026 review notes that these conventional approaches "may be insufficient to resolve symptoms in a timely manner and carry side effects." This is a clinically recognised limitation: some patients continue to experience uncontrollable high output despite optimal use of existing agents, and the side effect profile of drugs like codeine (constipation, dependence risk) or octreotide (injection requirement, cost) can limit their practicality for long-term use.

What Are GLP-1 Receptor Agonists?

GLP-1 receptor agonists are a class of drugs originally developed for type 2 diabetes management and, more recently, widely used for weight management. The drugs most people will recognise by name include semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), among others.

These drugs work by mimicking glucagon-like peptide-1, a hormone naturally released by the gut in response to food. One of GLP-1's effects is to slow gastric emptying and reduce the speed at which food and fluid move through the gastrointestinal tract. This mechanism is known as the ileal brake.

The reason researchers have started to ask whether GLP-1 receptor agonists could help with high-output stoma is exactly this mechanism. If the drug slows transit through the gut and reduces intestinal secretion, it could theoretically reduce the volume of output exiting through the stoma. The 2026 scoping review set out to examine what clinical evidence exists for this hypothesis.

The Scoping Review

The review, by Mao C, Wang AJ, and Le KDR, was conducted and reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. The researchers carried out a comprehensive literature search to identify peer-reviewed clinical studies evaluating the safety and efficacy of GLP-1 receptor agonists specifically for managing high stoma output (Mao C et al., The Journal of Surgical Research, 2026).

What it found. Three clinical studies met the inclusion criteria. Across those three studies:

• GLP-1 receptor agonist treatment was generally associated with a clinically meaningful reduction in stoma output of up to 50%.
• Several studies demonstrated reduced reliance on parenteral nutrition, meaning patients who had been dependent on intravenous nutrition showed improvements that allowed a reduction in or discontinuation of that support.
• Improvements in nutritional and anthropometric indices (markers of nutritional status and body composition) were also observed.
• Adverse effects reported were predominantly mild gastrointestinal symptoms, most commonly nausea. No serious adverse events were reported across the studies.

What the authors concluded. The review's conclusion is that there is emerging evidence supporting the role of GLP-1 receptor agonists in the management of high-output stoma. However, the authors are explicit about the limitations: the evidence base "is limited by small, heterogeneous and non-randomised studies." They call for "more robust prospective and adequately powered trials with standardised outcome measures" to establish efficacy, safety, and long-term clinical utility.

What This Means in Practice

The findings from this scoping review are early-stage evidence, not a clinical recommendation. A scoping review maps and summarises the existing literature on a topic; it does not synthesise that evidence into a firm conclusion about whether a treatment works in the way that a systematic review or randomised controlled trial would. Only three studies existed to include, and those studies were small and not randomised, meaning they cannot rule out that other factors (changes in diet, other medications, natural resolution) contributed to the improvements seen.

GLP-1 receptor agonists are not currently a standard treatment for high-output stoma in clinical guidelines. These drugs are also not free of side effects: nausea, vomiting, and abdominal discomfort are common, particularly when starting treatment or adjusting the dose. In stoma patients who are already struggling with fluid balance and nutrition, gastrointestinal side effects need to be carefully managed.

What the review does show is that this is now a recognised area of clinical research. The biological rationale is clear: GLP-1's role in slowing gut transit gives a plausible mechanism by which these drugs might help reduce stoma output. Researchers are now collecting clinical data to test whether that plausibility translates into a genuine, safe, and durable treatment benefit.

Why This Research Matters

High-output stoma is a condition with limited treatment options, and conventional treatments do not work for everyone. The potential for an established and widely available drug class to offer an additional management tool is worth tracking.

The review also notes the downstream benefits that emerged from the studies: reduced dependence on parenteral nutrition is a significant quality-of-life and clinical outcome for patients. Parenteral nutrition requires hospital-based or home IV access, carries infection risk through the catheter, and is both costly and burdensome. Any intervention that can meaningfully reduce reliance on it while improving nutritional status would represent a substantive advance for patients in this situation.

At the same time, three small non-randomised studies is a modest starting point. The research field will need larger, controlled trials before this becomes part of standard guidance. Patients and clinicians should watch for further results from prospective studies.

What This Study Cannot Tell You

A scoping review of three small studies cannot establish whether GLP-1 receptor agonists work for high-output stoma, what the optimal dose or drug within this class would be, how long treatment effects last, how they perform compared with existing treatments, or whether the benefits observed were caused by the drug rather than other factors. The studies included were heterogeneous, meaning they differed in their designs, patient populations, and how they measured outcomes, which makes direct comparison difficult.

The finding of up to 50% reduction in stoma output is drawn from the upper bound of what was observed in the reviewed studies, not an average or guaranteed outcome.

Your stoma care nurse and specialist team are best placed to advise on your current management and whether emerging research is relevant to your individual situation. Do not start or stop any medication based on this article.

AI-assisted curation; reviewed before publication. Always consult your doctor before making any changes to your healthcare.